Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 4002-4009

  Yin, Dali ^a   Wang, Xiao ^a   Konda, Bindu M ^a   Ong, John M ^a   Hu, Jinwei ^a   Sacapano, Manuel R ^a   Ko, Minhee K ^a   Espinoza, Andres J ^a   Lrvin, Dwain K ^a   Shu, Yan ^a   Black, Keith L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CITRULLINE; CYCLIC GMP; HYDROXYUREA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE DONOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN TUMOR BARRIER; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLIOMA; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD BRAIN BARRIER; BRAIN TUMOR; CAPILLARY PERMEABILITY; CELL CULTURE; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SCREENING; FISCHER 344 RAT; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ARGININE; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CITRULLINE; CYCLIC GMP; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; GLIOMA; HYDROXYUREA; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 52449089214     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1826     Document Type: Article

References (44)

1. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neuro-surg 1998;88:1-10.
2. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
3. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 1996;14:551 -9.
4. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004;100:1199-207.
5. Haroun Rl, Brem H. Local drug delivery. Curr Opin Oncol 2000;12:187-93.
6. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004;11:165-73.
7. Matsukado K, InamuraT, Nakano S, Fukui M, Bartus RT Black KL. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996;39:125-33; discussion 33-4.
8. NomuraT, InamuraT, Black KL. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 1994;659:62-6.
9. InamuraT, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1994;14:862-70.
10. Black KL, CloughesyT Huang SC, et al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997;86:603-9.
11. Ningaraj NS, Rao M, Hashizume K, Asotra K, Black KL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol ExpTher 2002;301:838-51.
12. TsuboiY,Takahashi M, IshikawaY Okada H.YamadaT. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Ther Apher 1998;2:297-9.
13. Ignarro LJ, Buga GM.Wood KS, Byms RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
14. Furchgott RF.Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3: 2007-18.
15. Wahl M, Schilling L. Regulation of cerebral blood
16. flow-a brief review. Acta Neurochir Suppl (Wien) 1993;59:3-10.
17. Oliver JA. Endothelium-derived relaxing factor contributes to the regulation of endothelial permeability. J Cell Physiol 1992;151:506-11.
18. Paul W, Douglas GJ, Lawrence L, et al. Cutaneous permeability responses to bradykinin and histamine in the guinea-pig: possible differences in their mechanism of action. Br J Pharmacol 1994;111:159-64.
19. Maeda H, NoguchiY, Sato K, AkaikeT. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994;85:331 -4.
20. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N EnglJ Med 1993;329:2002-12.
21. Janigro D.West GA, NguyenTS, Winn HR. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ Res 1994;75:528-38.
22. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 1996;56:4027-31.
23. Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Dermatol 1991;25:518-24.
24. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002;99:1144-9.
25. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
26. Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol 1997:52:1081 -6.
27. Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol 1999;55:1006-10.
28. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992:107:1092-5.
29. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994:298:249-58.
30. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-8.
31. Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 1978;235:H299 - 307.
32. Holstein GR, Friedrich VL, Jr., Martinelli GP. Monoclonal L-citrulline immunostaining reveals nitric oxide-producing vestibular neurons. Ann N Y Acad Sci 2001;942:65-78.
33. Anctil M, Poulain I, Pelletier C. Nitric oxide modulates peristaltic muscle activity associated with fluid circulation in the sea pansy Renilla koellikeri. J Exp Biol 2005;208:2005-17.
34. Scholz NL, deVente J,Truman JW, Graubard K. Neural network partitioning by NO and cGMP. J Neurosci 2001;21:1610-8.
35. Sugita M, Black KL. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res 1998;58:914-20.
36. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007;25:2295-305.
37. Ningaraj NS, Rao MK, Black KL. Adenosine 5́-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res 2003;63:8899-911.
38. Levin VA. Pharmacological principles of brain tumor chemotherapy. Adv Neurol 1976;15:315-25.
39. CokicVP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 2006;108:184-91.
40. Emerich DF, Snodgrass P, Dean RL, et al. Bradykinin modulation of tumor vasculature. I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy. J Pharmacol ExpTher 2001;296:623-31.
41. Matsukado K, Sugita M, Black KL. Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res1998;792:10-5.
42. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995;55:727-30.
43. Chi OZ.Wei HM, Sinha AK, Weiss HR. Effects of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia. Pharmacology 1994;48:367-73.
44. Onoue H, Katusic ZS. Role of potassium channels in relaxations of canine middle cerebral arteries induced by nitric oxide donors. Stroke 1997;28:1264-70; discussion 70-1.